Business
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein. “2026 has been a year of important progress and
About this update from Filana Therapeutics, Inc.
[{"type":"image","alt":"Filana Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Filana Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/ec6f71a08700bedee385c3d7ccb26ead"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kE7v18uI46Kkd18JkU65nA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/ec6f71a08700bedee385c3d7ccb26ead","width":300,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/kE7v18uI46Kkd18JkU65nA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/ec6f71a08700bedee385c3d7ccb26ead","width":300,"height":300}},"lazy":false},{"type":"text","content":"AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.","length":451,"tagName":"p"},{"type":"text","content":"“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options to patients with TSC-related epilepsy and their families,” said Rick Barry, President and Chief Executive Officer of Filana Therapeutics, Inc. “We believe the recent publication of preclinical data in Epilepsia and our presentation at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices further support the biological rationale behind simufilam and our approach to the potential treatment of TSC-related epilepsy. We remain focused on generating the necessary data to resolve the FDA’s Clinical Hold and advance the program. We are committed to keeping our stakeholders informed and look forward to sharing updates as they develop.”","length":847,"tagName":"p"},{"type":"text","content":"Recent Updates:","length":15,"tagName":"p"},{"type":"text","content":"Corporate Developments","length":22,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Name Change to Filana ...